CAR-T Followed by Bispecific Antibodies
Phase 2
42
about 5.7 years
18+
2 sites in NE, PA
About this study
Researchers are testing the safety and effectiveness of mosunetuzumab or a combination of obinutuzumab and glofitamab after CAR T-cell treatment in patients with DLBCL. The trial will last for approximately 2 years.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take glofitamab
- 2.Take mosunetuzumab
- 3.Take obinutuzumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
glofitamab, mosunetuzumab, obinutuzumab
injection, intravenous
Primary: Assessment of the percentage of subjects who experience hematologic dose limiting toxicity associated with early administration of Mosunetuzumab and glofitimab following SOC CAR-T Cell therapy in patients who stop therapy after 2 cycles., Assessment of the percentage of subjects who experience non-hematologic dose limiting toxicity associated with early administration of glofitimab following SOC CAR-T Cell therapy., Assessment of the percentage of subjects who experienced non-hematologic dose limiting toxicity associated with early administration of Mosunetuzumab following SOC CAR-T Cell therapy.
Oncology